Onderzoeker
Vibeke Kruse
- Disciplines:Kankerdiagnose, Kankertherapie
Affiliaties
- Vakgroep Inwendige ziekten en Pediatrie (Departement)
Lid
Vanaf1 okt 2018 → Heden - Vakgroep Inwendige ziekten (Departement)
Lid
Vanaf5 aug 2013 → 30 sep 2018
Publicaties
1 - 10 van 25
- Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors : the CHEERS phase 2 randomized clinical trial(2023)
Auteurs: Mathieu Spaas, Nora Sundahl, Vibeke Kruse, Sylvie Rottey, Daan De Maeseneer, Fréderic Duprez, Yolande Lievens, Veerle Surmont, Lieve Brochez, Dries Reynders, et al.
Pagina's: 1205 - 1213 - Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures(2021)
Auteurs: Annabel Meireson, Simon Tavernier, Sofie Van Gassen, Nora Sundahl, Annelies Demeyer, Mathieu Spaas, Vibeke Kruse, Liesbeth Ferdinande, Jo Van Dorpe, Benjamin Hennart, et al.
- Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS) : study protocol for a phase 2, open-label, randomized controlled trial(2021)
Auteurs: Mathieu Spaas, Nora Sundahl, Eva Hulstaert, Vibeke Kruse, Daan De Maeseneer, Annabel Meireson, Lieve Brochez, Dries Reynders, Els Goetghebeur, Robbe Van den Begin, et al.
- A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases(2020)
Auteurs: Yanina Jansen, Vibeke Kruse, Jurgen Corthals, Kelly Schats, Pieter-Jan van Dam, Teofila Seremet, Carlo Heirman, Lieve Brochez, Mark Kockx, Kris Thielemans, et al.
Pagina's: 2589 - 2598 - Recommendations for skin cancer consultation and surgery during COVIDU+201019 pandemic(2020)
Auteurs: Lieve Brochez, J.F. Baurain, V. Del Marmol, A. Nikkels, Vibeke Kruse, F. Sales, M. Stas, A. Van Laethem, M. Garmyn
Pagina's: 1876 - 1878 - Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma(2019)
Auteurs: Nora Sundahl, Teofila Seremet, Bart Neyns, Liesbeth Ferdinande, Annabel Meireson, Lieve Brochez, Vibeke Kruse, Piet Ost
Pagina's: 828 - 835 - Throughput efficiency and service quality after process redesign at a cancer day care unit: Two sides of the coin?(2019)
Auteurs: Kaat De Pourcq, Paul Gemmel, Jeroen Trybou, Vibeke Kruse
- Immune checkpoint blockade for organ transplant patients with advanced cancer : how far can we go?(2019)
Auteurs: Pauline De Bruyn, Dirk Van Gestel, Piet Ost, Vibeke Kruse, Lieve Brochez, Hans Van Vlierberghe, Arnaud Devresse, Véronique del Marmol, Alain Le Moine, Sandrine Aspeslagh
Pagina's: 54 - 64 - Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma(2018)
Auteurs: Nora Sundahl, Katrien De Wolf, Vibeke Kruse, Annabel Meireson, Dries Reynders, Els Goetghebeur, Mireille Van Gele, Reinhart Speeckaert, Benjamin Hennart, Lieve Brochez, et al.
Pagina's: 906 - 915 - The impact of logarithmic dose banding of anticancer drugs on pharmacy compounding efficiency at Ghent University Hospital(2018)
Auteurs: Barbara Claus, Kaat De Pourcq, NELE CLOTTENS, Vibeke Kruse, Paul Gemmel
Pagina's: 334 - 336